Antriabio Inc., of Louisville, Colo., acquired the rights to Berkeley, Calif.-based Activesite Pharmaceuticals Inc.'s plasma kallikrein inhibitor (PKI) program so it can develop, file, manufacture, market and sell products for diabetic macular edema and other conditions. It will pay Activesite $750,000 up front and various milestone payments ranging from $1 million to $10 million. It could also provide Activesite with royalty payments of 2 percent of sales for any products that use the PKI program.